Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD 38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma

NCT01421186 is registered in ClinicalTrials.gov with MorphoSys AG as lead sponsor.

NCT NCT01421186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01421186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD 38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma
Lead sponsor
MorphoSys AG
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2011
Completion date
August 31, 2020
Enrollment
91 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma